|
[1]
|
The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022;7(5):396 − 415. http://dx.doi.org/10.1016/S2468-1253(21)00472-6CrossRef
|
|
[2]
|
Bian DD, Zhou HY, Liu S, Liu M, Duan C, Zhang JY, et al. Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals. Medicine 2017;96(34):e7885. http://dx.doi.org/10.1097/MD.0000000000007885CrossRef
|
|
[3]
|
National Disease Control and Prevention Administration. The national work plan for elimination of hepatitis C as a public health threat (2021–2030). 2021. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml. [2023-8-20]. (In Chinese). |
|
[4]
|
Lebovics E, Torres R, Porter LK. Primary care perspectives on hepatitis C virus screening, diagnosis and linking patients to appropriate care. Amer J Med 2017;130(2):S1 − 2. http://dx.doi.org/10.1016/j.amjmed.2017.01.001CrossRef
|
|
[5]
|
Carvalho-Louro DM, Soares EB, Trevizoli JE, Marra TMG, da Cunha ALR, Rodrigues MP, et al. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil. BMC Infect Dis 2020;20(1):114. http://dx.doi.org/10.1186/s12879-020-4809-2CrossRef
|
|
[6]
|
Kim BK. How to optimize the care cascade of hepatitis C virus infection. Gut Liver 2022;16(6):809 − 10. http://dx.doi.org/10.5009/gnl220452CrossRef
|
|
[7]
|
Sun J, Cheng HC, Hassan MRA, Chan HK, Piedagnel JM. What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 - a narrative review. Lancet Reg Health West Pac 2021;16:100261. http://dx.doi.org/10.1016/j.lanwpc.2021.100261CrossRef
|
|
[8]
|
Kapadia SN, Katzman C, Fong C, Eckhardt BJ, Guarino H, Mateu-Gelabert P. Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross-sectional study. J Viral Hepatitis 2021;28(2):326 − 33. http://dx.doi.org/10.1111/jvh.13437CrossRef
|
|
[9]
|
Malnick S, Maor Y, Melzer E, Tal S. Chronic hepatitis C in the aged: much ado about nothing or nothing to do? Drugs Aging 2014;31(5):339 − 47. http://dx.doi.org/10.1007/s40266-014-0170-8CrossRef
|
|
[10]
|
Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34(5):730 − 9. http://dx.doi.org/10.1016/S0168-8278(00)00097-0CrossRef
|